OSLO: Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announces that Carlos de Sousa, MD, has been appointed as the new Chief Executive Officer. Dr. de Sousa joins Ultimovacs as a seasoned industry executive with 30 years of experience ranging from leadership positions at international pharmaceutical companies such as Pfizer, Novartis and Nycomed/Takeda,…